about
PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development.Nonclinical development of biopharmaceuticals.PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers.Preclinical development of therapeutic biologics.Pharmacokinetics, metabolism and distribution of PEGs and PEGylated proteins: quo vadis?Nonclinical safety testing of biopharmaceuticals--Addressing current challenges of these novel and emerging therapies.Leverage nonclinical development of bispecifics by translational science.Mechanistic Modeling of the Pharmacodynamic and Pharmacokinetic Relationship of Tissue Factor Pathway Inhibitor-Neutralizing Antibody (BAY 1093884) in Cynomolgus Monkeys.Non-clinical Safety Evaluation of Biotherapeutics - Challenges, Opportunities and new Insights.New challenges and opportunities in nonclinical safety testing of biologics.Current challenges and opportunities in nonclinical safety testing of biologics.Biotherapeutics in non-clinical development: Strengthening the interface between safety, pharmacokinetics-pharmacodynamics and manufacturing.DNA adduct formation of selected sex steroids in human liver slices in vitroUse of precision cut human liver slices for studying the metabolism and genotoxic potential of xenobiotics by means of the (32)P-postlabelling technique: steps towards method validation using testosterone and 2-aminofluorenePharmacokinetics, excretion, distribution, and metabolism of 60-kDa polyethylene glycol used in BAY 94-9027 in rats and its value for human predictionPEGylated biologics in haemophilia treatment: Current understanding of their long-term safety
P50
Q27691352-C9D24E4B-2AB1-480F-A5B9-BA4C8C70E2ECQ37620496-0BBF1FCD-0390-41ED-9BFE-E5B28107323EQ38036746-BE3E6342-9ADB-49C9-86FD-DC65958D9DBCQ38088310-70D330AB-CEC4-4C3A-A8D7-DFC724A96A45Q38220218-267E0892-4B1A-44AC-AB0F-1BE272E5628AQ38980247-0E7D0376-61EF-4CFE-A983-C995424BB6BFQ39039545-513C4D7B-2D6E-483F-B717-4B243BD77CF2Q45867817-BF86BC6A-14FD-4952-B458-E9F64CFA0CDAQ46495190-3C3C21C9-545A-4599-8808-A3F1594B6079Q46902769-9BDCFE77-2889-4F7F-83B8-62A45FFD3C88Q47785850-44E3F03A-E5AF-4F5D-8928-B90271C99BE6Q49885070-88AD1154-A27F-41E2-85FA-DD9679888706Q84589474-DC4AB268-C41C-40E7-81BE-87D8DA8C8AABQ87147443-B3846214-8741-4878-A8FE-779021B86495Q91091940-6FB00537-5B4C-4F98-9D6A-F08EAE58C58EQ91336850-443218D6-9F20-4CE1-8BCC-26BD25A1E4D1
P50
description
investigador
@es
researcher
@en
name
A Baumann
@en
type
label
A Baumann
@en
prefLabel
A Baumann
@en
P31
P496
0000-0003-3034-4288